At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 474 enrolled
Drug / intervention
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older)
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Jun 2, 2010·Updated May 23, 2012
In Brief
A Phase 3 clinical trial evaluating Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol and Placebo Nasal Aerosol for Rhinitis, Allergic, Perennial. Completed, enrolled 474 participants across 35 sites.
Detailed Summary
The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of perennial allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Perennial
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionOct 2010
TodayJul 2026
First PostedJun 2, 2010
Enrollment StartMay 1, 2010
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.1 years ago
Interventions
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosoldrug
Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
Placebo Nasal Aerosoldrug
HFA Vehicle Aerosol